Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720460 | PMC |
| http://dx.doi.org/10.1515/rir-2024-0027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanism of low molecular weight impurity formation in an IgG1 monoclonal antibody formulation.
J Pharm Sci
January 2025
Formulation and Drug Product Development, Biologics, Dr. Reddy's Laboratories, Hyderabad, India. Electronic address:
Formulation robustness study was performed for a biosimilar monoclonal antibody (IgG1) manufactured at Dr. Reddy's Laboratory, where the pH and concentration level of excipients in the drug product formulation were systematically varied from the target formulation. It was observed that the IgG1 formulation having relatively low pH and high citrate (buffer salt) concentration were predisposed to the formation of low molecular weight impurities.
View Article and Find Full Text PDFCost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
J Neurol
January 2025
Department of Neurology, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Background: Natalizumab (NAT) is an established disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, its use involves complex decision-making, often leading to initial use of lower efficacy therapies. Recently, the first biosimilar NAT was approved, enabling competitive pricing.
View Article and Find Full Text PDFCross-sectional patient survey of biological medicine users in Finland to investigate the types of guidance needed by patients in order to carry out their treatment successfully.
BMJ Open
January 2025
Oriola Finland Oy, Espoo, Uusimaa, Finland
Background: The use of new biological medicines as standard treatment is expected to increase substantially and cover new therapeutic indications in the near future. Interchange of biological medicines in pharmacies increases the need for patient guidance.
Objectives: The study aims to gain a patient perspective on biological medicine users' needs and wishes regarding patient guidance by exploring what kind of information patients wish to receive and to further investigate the potential differences in needs between originator biological medicine users and biosimilar users.
The potential for biosimilars to address unmet clinical need - Is the developed world missing out?
Rheumatol Immunol Res
December 2024
Department of Rheumatology, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom.
Biosimilars can potentially increase patient treatment options, allowing access to expensive biologic medications. As frontline caregivers, nurses are uniquely positioned to educate patients on their safety and effectiveness. This article discusses biosimilars and standard terms, their development process, and strategies for nurses to provide effective patient education about these medications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!